Mutational Profile in Romanian Patients with Hemophilia A
by
, ,
Andra Grigore
1,2,*,
Mihaela Dragomir
2,
Onda-Tabita Călugăru
2,
Dumitru Jardan
3,
Cerasela Jardan
2,4,
Melen Brînză
2,
Paul Bălănescu
5 and
Daniel Coriu
1,2 1
Hematology (Clinic and Laboratory) Discipline-Fundeni Clinical Institute, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
2
Department of Hematology and Bone Marrow Transplant, Fundeni Clinical Institute, 022328 Bucharest, Romania
3
Molecular Biology Laboratory, Medlife, 010093 Bucharest, Romania
4
Pediatrics Discipline-Fundeni Clinical Institute, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
5
Internal Medicine Discipline-Colentina Clinical Hospital, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(15), 8366; https://doi.org/10.3390/ijms25158366
Submission received: 30 June 2024
/
Revised: 25 July 2024
/
Accepted: 30 July 2024
/
Published: 31 July 2024
(This article belongs to the Special Issue State-of-the-Art Molecular Biology in Romania)
Abstract
:Hemophilia A (HA) is an X-linked recessive bleeding disorder caused by mutations in the F8 gene, resulting in deficient or dysfunctional factor VIII (FVIII). This study aimed to characterize the mutational profile of HA in Romanian patients using next-generation sequencing (NGS) and multiplex ligation-dependent probe amplification (MLPA). A total of 107 patients were analyzed, revealing pathogenic or likely pathogenic variants in 96.3% of cases. The identified mutations included missense (30.5%), nonsense (9.1%), small deletions (6.4%), small insertions (2.1%), splice-site variants (4.3%), large deletions (1.6%), and large duplications (1.1%). Large intron inversion was previously found in 37.5% of the patients. Novel variants accounted for 21.5% of identified mutations, expanding the spectrum of F8 variants in this population. This study underscores the genetic heterogeneity of HA and provides insights into genotype–phenotype correlations, aiding in clinical management and prenatal diagnosis.
1. Introduction
Hemophilia A (HA), an X-linked recessive bleeding disorder, is characterized by a deficiency or dysfunction of clotting factor VIII (FVIII). This genetic disorder affects almost exclusively males, with an incidence of approximately 1 in 5000 live male births worldwide. The clinical phenotype of HA varies from mild to moderate and severe forms depending on the residual coagulant activity levels of FVIII (FVIII:C). Severe HA is characterized by FVIII:C levels below 1%, resulting in spontaneous bleeding episodes. Moderate HA is defined by FVIII:C levels ranging from 1% to 5%, leading to a bleeding tendency even with minor trauma. Patients with mild HA have FVIII:C levels between 5% and 40%, excessive bleeding occurring only in case of hemostatic challenges like trauma or surgery. Hemorrhages predominantly involve the joints and muscles but can also affect internal organs [1].
Factor VIII (FVIII) performs an essential regulatory function within the hemostatic system by enhancing the proteolytic activation of factor X (FX) through activated factor IX (FIXa) on platelet surfaces, during the amplification phase of coagulation [2]. Synthesized primarily in liver sinusoidal endothelial cells [3], FVIII is released as a 2351-amino-acid single-polypeptide chain, from which a 19-amino-acid signal peptide is removed. The mature FVIII protein has the domain structure A1-a1-A2-a2-B-a3-A3-C1-C2 [4]. The heavy chain (A1-a1-A2-a2-B) and the light chain (a3-A3-C1-C2) are non-covalently bound. The heavy chain displays structural heterogeneity due to limited proteolysis occurring within the B domain [5]. B domain plays a significant role in the synthesis, secretion, and stability of FVIII but is not required for its coagulant activity and is cleaved during activation. In the bloodstream, FVIII exists as a heterodimer bound to von Willebrand factor (VWF), which protects it from degradation and helps localize it at sites of vascular injury [6]. Activation of FVIII involves thrombin-mediated cleavage at three specific arginine residues (R372, R740, and R1689), transforming it into an active heterotrimer (A1-a1, A2-a2, A3-C1-C2). This active form plays a critical role in the coagulation process. Deactivation occurs through further cleavage by FX, by activated factor IX (FIX), or by activated protein C, ensuring controlled clot formation [7].
Factor VIII (FVIII) is encoded by the F8 gene, located at the distal end of the long arm of the X chromosome (Xq28). The F8 gene, first cloned in 1984 by Gitschier and colleagues, is structurally complex, spanning 186 kb of genomic DNA and consisting of 26 exons and 25 introns [8]. Mutations in the F8 gene that lead to FVIII deficiency are heterogenous and include point mutations, deletions, insertions, and inversions, with intron 22 and intron 1 inversions being particularly prevalent, especially in severe HA cases. These inversions account for approximately 50% of severe HA cases and 30% of all HA cases [9,10]. Besides large intron inversions, two other significant hotspots have been identified: CpG dinucleotides and stretches of adenine nucleotides [11,12,13].
To date, 3052 unique mutations of various types, excluding inversions, have been documented in the European Association for Haemophilia and Allied Disorders (EAHAD) Coagulation Factor VIII Variant Database—https://f8-db.eahad.org/ (accessed on 12 June 2024). The prevalence of genetic variants in HA includes 66.2% point mutations, 23.4% deletions, 6% duplications, 1.6% insertions, and 1.3% indels, distributed across all exons [14].
The development of neutralizing antibodies (inhibitors) against FVIII complicates treatment, affecting approximately 20–30% of patients with severe HA on replacement therapy during their lifetime and 5–10% of patients at any given time [14,15]. This phenomenon poses substantial clinical challenges by rendering standard treatments ineffective. The risk of inhibitor formation is multifactorial, with genetic factors, particularly the type and localization of F8 mutations, playing pivotal roles [16,17].
In Romania, the national registry for patients with hemophilia is currently under development, thus precluding access to data from this source. According to the 2023 Annual Global Survey Report by the World Federation of Hemophilia, Romania has 1615 individuals diagnosed with HA, with 71 of these patients presenting active inhibitors. Nevertheless, specific data regarding the severity of the disease in this patient population are not available [18]. Moreover, in Romanian patients, the genetic landscape of HA is largely unexplored beyond the known presence of large intron inversions [19]. The current study aims to investigate the mutational profile in a cohort of Romanian HA patients using next-generation sequencing (NGS) and multiplex ligation-dependent probe amplification (MLPA). We expect to expand the spectrum of F8 variants and provide valuable insights for both clinical management of HA patients and prenatal diagnosis in affected families. Characterizing prevalent mutations in this population will enhance our understanding of genotype–phenotype correlations and contribute to more personalized and effective therapeutic approaches.
2. Results
Molecular analysis revealed pathogenic or likely pathogenic variants in 103 out of 107 individuals, yielding a variant detection rate of 96.3%. In total, we identified 75 distinct variants, comprising 38 missense variants, 14 nonsense variants, 9 small deletion variants, 4 small duplication variants, 5 splice-site variants, 3 large deletions, and 2 large duplications. A comprehensive summary of the identified F8 gene alterations is provided in Table 1.
The distribution of variants spanned all exons of the F8 gene, except for exons 6, 15, 20, 21, and 26 (Figure 1). Mutations were unevenly distributed, with exon 14 harboring the highest proportion (30.8%), followed by exon 8 (10.8%).
Missense variants were the most frequent type of mutation, accounting for 50.67% of the total variant types. Among these, 18 variants were classified as pathogenic and 20 as likely pathogenic. The severity distribution among patients with missense variants showed that 52.7% had severe HA, 33.3% had moderate HA, and 14% had mild HA. Only 3.5% (2/57) of patients with missense variants developed inhibitors, with the mutations occurring in the A3 and C2 domains.
Nonsense variants comprised 18.7% of the identified mutations and were all classified as pathogenic. All patients with nonsense variants exhibited severe HA. Inhibitors were present in 17.6% of these cases (three patients), with the mutations occurring in the B, A3, and C2 domains.
Small deletions constituted 12% of the identified variants, including four single-nucleotide deletions, one two-nucleotide deletion (CT), and two four-nucleotide deletions (TGTT, AAAT). All small deletions were pathogenic, with most patients manifesting severe HA, except for one case with moderate disease. Inhibitors developed in one patient (8.33%) with a mutation in the A3 domain.
Small duplications accounted for 5.33% of the variants. All were pathogenic, and all patients had severe HA. None of the patients with small duplications developed inhibitors.
Splice-site variants made up 6.67% of the identified mutations and were all likely pathogenic. Six patients had severe HA, and two had moderate HA. No inhibitors were detected in these patients.
Three patients with severe HA exhibited large deletions detected by MLPA. These deletions included the first 6 exons, the first 10 exons, and exons 5 and 6, respectively. The deletion of exons 1–10 had not been previously reported. One of these patients developed inhibitors.
Two patients had large duplications detected by MLPA, involving exons 12–14 and 16–22. Both patients had severe HA, and one patient developed inhibitors.
We identified 23 novel variants, including 10 missense variants, 3 nonsense variants, 5 small deletions, 2 splice-site variants, 1 large deletion, and 2 large duplications. All were classified as pathogenic or likely pathogenic, with five novel variants being recurrent. A summary of these variants is provided in Table 1.
By integrating the results from this study with those of the previously published investigation [19], we examined the mutational profile of 187 patients with HA, comprising 83.4% with severe HA, 12.3% with moderate HA, and 4.3% with mild form of the disease. Large intron inversions were detected in 37.4% of the patients, with inversions in intron 22 occurring in 34.8% and inversions in intron 1 in 2.7%. Missense mutations were identified in 30.5% of the cohort, while nonsense mutations were present in 9.1%. Small deletions were found in 6.4% of patients, small insertions in 2.1%, large deletions in 1.6%, large duplications in 1.1%, and splice-site mutations in 4.3%. The mutational profile remained unknown in 7.5% of the patients: pathogenic variants in the F8 gene were undetectable in four patients (2.1%), while insufficient DNA for further analysis hindered examination in ten patients (5.4%). These findings are depicted in Figure 2.
In patients with severe HA, the intron 22 inversion emerged as the most prevalent mutation, detected in 41.7% of cases. This was succeeded by missense mutations in 19.2%, nonsense mutations in 10.9%, small deletions in 7.1%, splice-site mutations in 3.8%, intron 1 inversion in 3.2%, small insertions in 2.6%, large deletions in 1.9%, and large duplications in 1.3% of patients. These results are illustrated in Figure 3.
Missense variants were the most prevalent genetic defects in patients with mild/moderate forms of HA, identified in 87.1% of patients. These were followed by splice-site mutations, which were found in 6.5% of cases, and small deletions, detected in 3.2% of cases. These findings are presented in Figure 4.
Overall, inhibitors were detected in 17 patients, constituting 9.09% of the cohort examined. With the exception of one patient who exhibited a moderate form of HA, all patients with inhibitors (94.12%) presented with severe form of the disease. Inhibitors were identified in 10.26% of patients with severe HA and in 3.23% of those with mild to moderate disease. The distribution of inhibitors according to the type of mutation is presented in Table 2. Due to the small sample size, differences in inhibitor occurrence were not statistically significant (p = 0.19).
3. Discussion
We conducted a comparative analysis of our findings with those from larger studies. Specifically, we compared our results across all severities of HA with the data published by Oldenburg et al. [20], which included 846 individuals with varying HA severities, and by Bach et al. [21], who studied 2671 patients with different HA severities. Additionally, we compared our results in patients with severe HA with those from a meta-analysis by Gouw et al. [22], which encompassed 5383 patients with severe HA, and with a study by Johnsen et al. involving 1272 patients with HA [23]. For mild and moderate HA, we compared our findings with those of Johnsen et al., who analyzed 1048 patients with mild to moderate HA [24]. The comparative data are presented in Table 3. Overall, our results align with these studies. However, some discrepancies, such as the higher prevalence of intron 1 inversion and the increased prevalence of small deletions and insertions in our severe HA cohort, may be attributed to the bias introduced by the smaller number of patients with specific types of mutations.
In total, 21.5% of the identified mutations in the F8 gene are novel, emphasizing the broad spectrum of genetic defects within the F8 gene. Among the newly identified mutations, five are recurrent and may be characteristic of our population. Further investigation is required to validate this hypothesis. The novel c.641T>G variant was found in four unrelated patients with varying HA severities (one patient with severe HA, two patients with moderate disease, and one with a mild form of HA). Two novel variants were discovered simultaneously in one patient, both located in exon 14 and coding for the A2 domain (c.2148T>A and c.2189G>C). Both variants were classified as likely pathogenic. Additional investigation is required to determine the contribution of each variant to the pathogenesis of severe HA. Notably, the identification of 23 novel variants expands the current mutation database, providing new insights into the genetic underpinnings of HA. To the best of our knowledge, this is the first report detailing the mutational profile of Romanian patients with HA.
Most missense variants were located in the A1 and A2 domains (65.8%), with no variant found in the B domain. The A1 and A2 domains play a critical role in FVIII activity and are particularly prone to mutations [24,25]. In contrast, mutations causing HA are rarely found in the B domain, which lacks procoagulant activity and is partially cleaved from the mature FVIII protein [26,27]. Nonsense variants were found in diverse regions, including the signal peptide, a1, A2, B, A3, C1, and C2 domains. The B domain was the most frequent site (28.6%), leading to premature protein termination [10].
Approximately one-third of missense variants (31.58%) and 42.9% of nonsense mutations occurred in CpG dinucleotides coding for arginine. Significantly, the p.(Arg391His) variant was recurrent, being detected in seven unrelated patients. Altogether, CpG dinucleotide hotspots were mutated in 34.6% of the single-nucleotide polymorphisms, our finding being consistent with reports that 40% of point mutations in the F8 gene occur at CpG sites, which comprise only 2% of the coding sequence [28]. Methylation of cytosine at these sites can lead to deamination, converting cytosine to thymidine, which is less efficiently recognized by DNA repair mechanisms. This results in a high mutation rate, particularly impacting arginine residues encoded by CpG-containing codons [11,12].
Small deletions and insertions are frequently observed in repetitive sequences of adenine nucleotides, notably within exon 14 at codons 1191–1194, 1439–1441, and 1588–1590. These mutations arise from polymerase slippage errors during DNA replication or RNA transcription. Such errors may lead to a mitigated phenotype of severe HA with rare bleeding, due to endogenous restoration of the reading frame and subsequent production of low levels of functional FVIII protein [13]. In our study, Poly A-runs were involved in 44.4% of small deletions. In most deletions (five out of nine), the mutation was localized in the region of exon 14, coding for the B domain. All small duplications involved Poly A-runs regions from exon 14, coding for the B domain. Consequently, our findings confirm the existence of a hotspot for F8 mutations within regions containing A-stretches.
No genetic cause was found in 4 cases out of 107: three cases of severe HA and one case with moderate disease. Common inversions, nucleotide substitutions in all F8 gene exons and adjacent intronic regions, large deletions, and insertions were excluded. We cannot rule out deep intronic variants leading to alternative splicing [29], pathogenic variants in regulatory genes, or unique inversions undetectable by NGS and MLPA techniques. HA patients without detectable F8 gene defects may constitute less than 10% of the sample population [30,31,32,33]. Other possible causes include mutations in other genes causing an HA-like phenotype, such as mutations in von Willebrand factor affecting the FVIII binding site in von Willebrand disease (VWD) type 2 Normandy (2N) [34,35], or mutations in the LMAN1 gene (lectin, mannose-binding 1) [36,37] or MCFD2 gene (multiple coagulation factor deficiency 2 protein) [38], leading to combined deficiencies of factor V and FVIII. Further investigation of these patients is necessary to determine the underlying cause of FVIII deficiency.
Mutations that result in the absence of a functional gene product, such as large deletions, large intron inversions, nonsense mutations, non-A-run small deletions, and splice-site mutations, typically manifest as severe HA and increase the likelihood of inhibitor formation. In particular, large deletions spanning multiple domains carry an extremely high risk of developing inhibitors. On the other hand, missense mutations and small deletions/insertions within the A-runs carry a lower risk of inhibitor development, as they may result in the production of an altered but partially functional protein, which can sometimes induce immune tolerance [24,39,40]. In missense mutations, the risk of developing inhibitors depends more on the mutation’s location rather than the severity of the patient’s hemophilia phenotype. Thus, missense mutations located in the light chain pose a significantly higher risk of inhibitor formation, about four times greater compared to mutations elsewhere. In these cases, inhibitor development often occurs later in adulthood and patients typically have a poor response to immune tolerance therapies [24,41].
Garagiola et al. [42] proposed categorizing F8 mutation types into three risk groups: high-risk (large insertions/deletions affecting multiple exons and nonsense mutations on the light chain), intermediate-risk (large insertions/deletions involving a single exon, nonsense mutations on the heavy chain, and large intron inversions), and low-risk (small insertions/deletions, missense mutations, and splice-site mutations). In our cohort, 4.8% (9/187) of patients fell into the high-risk group, 33% of them (3/9) developing inhibitors. The intermediate-risk group comprised 43.3% of patients (81/187), with inhibitors present in 12.3% of them (10/81). The low-risk group included 43.3% of the patients (81/187), with a 3.7% inhibitor rate (3/81).
The patients with large duplications could not be classified in the proposed risk groups. The low prevalence of large duplications might make it difficult to assess the risk of inhibitor development in these patients. In a large study of 2671 patients with HA, large duplications were detected in only 0.64% of the cases [21]. In our study, one of the two patients with large duplications developed inhibitors. Interestingly, the duplicated region (exons 16–22) codes for the light chain. We believe that the hypothesis that duplications in the region encoding the light chain increase the risk of inhibitor development deserves future study in large patient cohorts.
Besides the aforementioned patient with a large duplication in the light chain, five other patients with mutations in the light chain developed inhibitors: two patients with missense variants, two patients with nonsense variants, and one patient with small deletion. Altogether, 35.3% of the patients with inhibitors had mutations in the light chain. Therefore, our study confirms the importance of the light chain in the immunogenicity of FVIII.
The relatively small number of patients with inhibitors in our study limits the statistical power to draw definitive conclusions about the correlation between specific mutations and inhibitor development. Larger cohorts are necessary to validate these findings and to better understand the risk factors associated with inhibitor formation.
The risk stratification of mutations, based on their type and location, provides valuable prognostic information concerning the likelihood of inhibitor formation. This stratification can guide clinical management and therapeutic strategies, optimizing patient outcomes.
Table 4 presents a comparative analysis of the frequency of inhibitor development for each type of mutation in our population, juxtaposed with data from two extensive studies [22,24]. The frequency of inhibitors associated with nonsense mutations, missense variants, and small deletions and insertions aligns with published data. Our findings confirm that inhibitors are more prevalent when mutations are localized in the light chain and when small deletions and insertions occur in regions outside the adenine stretches. Discrepancies in the frequency of inhibitor occurrence were observed in patients with large rearrangements. Specifically, the incidence of inhibitors was lower in those with intron 22 inversion (7 out of 65) and large deletions (one out of three) but higher in those with intron 1 inversion (two out of five). We hypothesize that these variations compared to other studies may be attributable to the limited sample size in our cohort. However, this assumption requires further research involving a larger cohort of patients.
4. Materials and Methods
4.1. Patients
The study employed a cross-sectional design and encompassed 107 apparently unrelated patients previously diagnosed with HA. These patients successively attended one of the following national centers for hemophilia: Fundeni Clinical Institute, “Prof. Dr. Ion Chiricuta” Institute of Oncology in Cluj Napoca, “Sf. Spiridon” Clinical Emergency Hospital in Iasi, and “Cristian Serban” Medical Center for Evaluation and Rehabilitation for Children in Buzias. We excluded from our study cohort any related patients, as well as 70 patients who tested positive for large intron inversions (intron 22 inversion and intron 1 inversion). Additionally, 10 patients who tested negative for large intron inversions were excluded due to insufficient DNA for further analysis. Among the 107 patients, 71% had severe HA, 21.5% had moderate HA, and 7.5% had mild forms of HA. A family history of HA was reported in 33 cases (30.8%), while 61 patients (57%) had no family history of HA, and in 13 patients (12.2%) the family history was uncertain.
The patient group varied in terms of age and the treatment plans they were following. The mean age was 42 years (SD = 15). The majority of patients were on prophylactic substitution therapy, while 35% received treatment on demand. Patients were systematically screened for inhibitors according to the national protocol for HA, with inhibitors identified in eight patients (7.6%) using the Bethesda assay.
4.2. Samples/DNA Extraction
This study was conducted in the Molecular Biology Laboratory of the Hematology Department in Fundeni Clinical Institute. Peripheral whole blood samples were collected in EDTA tubes, followed by genomic DNA extraction using the PureLink Genomic DNA Mini Kit (Invitrogen, Waltham, MA, USA) according to the manufacturer’s instructions. DNA purity and concentration were subsequently assessed using a NanoDrop-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA).
4.3. Next-Generation Sequencing (NGS)
Primers were designed using Primer-BLAST software—https://www.ncbi.nlm.nih.gov/tools/primer-blast/ (accessed on 19 May 2020) to target amplification across all exons and exon–intron junctions of the F8 gene via polymerase chain reaction (PCR). The PCR products were purified using the ProNex® Size-Selective Purification System (Promega, Madison, WI, USA) and subsequently indexed with the IDT for Illumina kit (Illumina, San Diego, CA, USA). The quality and quantity of the samples were assessed using a Qubit™ 4 Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). Following equimolar pooling of the samples, libraries were sequenced on the Illumina MiSeq platform, entailing a 500-cycle double-indexed paired-end run. For demultiplexing, CASAVA 1.8 software (Illumina, San Diego, CA, USA) was employed. Subsequently, the resulting FASTQ files underwent alignment to the GRCh38 reference genome using DNASTAR Lasergene 17.2 software, followed by visualization using IGV 2.16.0 software. The identified variants were annotated using the Ensembl Database and HGVS nomenclature.
4.4. Variant Interpretation
Variant interpretation followed the guidelines of the American College of Medical Genetics (ACMG) [43]. Variants were categorized as pathogenic (P), likely pathogenic (LP), variant of uncertain significance (VUS), benign (B), or likely benign (LB), utilizing 26 criteria of varying strength: 15 pathogenic (PVS1, PS1-4, PM1-6, PP1-4) and 11 benign (BA1, BS1-4, BP1-7 except BP6).
We consulted the ClinVar Database (National Library of Medicine, Bethesda, MD, USA) and the European Association for Hemophilia and Allied Disorders (EAHAD) Factor VIII Gene (F8) Variant Database—https://f8-db.eahad.org/index.php (accessed on 5 May 2024) to ascertain whether the variants had been previously reported. We examined the Genome Aggregation Database (gnomAD)—http://gnomad-sg.org/ (accessed on 5 May 2024) to verify the absence or the low incidence of the variant in the general population. Domain information was retrieved from UniProt—https://www.uniprot.org/ (accessed on 6 April 2024).
4.5. Bioinformatic Tools
The potential deleterious effects of the variants were assessed in silico utilizing the following prediction tools: PolyPhen 2.0—http://genetics.bwh.harvard.edu/pph2/ (accessed on 10 June 2024), SIFT—https://sift.bii.a-star.edu.sg/ (accessed on 10 June 2024), and MutationTaster—https://www.mutationtaster.org/ (accessed on 10 June 2024).
4.6. MLPA Analysis
For patients with suspected large deletions or duplications, or those who tested negative by NGS, a multiplex ligation-dependent probe amplification (MLPA) assay was performed to detect complex rearrangements in the F8 gene. We utilized the SALSA MLPA Probemix P178-B4 F8 kit (MRC Holland, Amsterdam, The Netherlands) in accordance with the manufacturer’s instructions on a SeqStudio Genetic Analyzer (Applied Biosystems, Waltham, MA, USA). Results were analyzed using Coffalyser.Net software v.240129.1959 (MRC Holland).
4.7. Statistical Analysis
The analysis of data was carried out using IBM SPSS Statistics software (version 27) on Mac OS (IBM Corp., Armonk, NY, USA).
Author Contributions
Conceptualization, A.G. and D.C.; methodology, A.G.; validation, D.J.; formal analysis, P.B. and O.-T.C.; investigation, A.G., M.D., O.-T.C., C.J. and D.J.; resources, M.B. and M.D.; writing—original draft preparation, A.G.; writing—review and editing, A.G. and D.C.; visualization, O.-T.C. and P.B.; supervision, D.C.; project administration, A.G. All authors have read and agreed to the published version of the manuscript.
Funding
This research was funded by the Romanian Society of Hematology.
Institutional Review Board Statement
This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Fundeni Clinical Institute (approval number 747 from 8 January 2018).
Informed Consent Statement
Informed consent was obtained from all subjects involved in this study.
Data Availability Statement
Data used in this study may be provided by the corresponding author upon reasonable request.
Acknowledgments
Publication of this paper was supported by the University of Medicine and Pharmacy Carol Davila, through the institutional program Publish not Perish.
Conflicts of Interest
The authors declare no conflicts of interest.
References
- Mannucci, P.M.; Tuddenham, E.G. The Hemophilias—From royal genes to gene therapy. N. Engl. J. Med. 2001, 344, 1773–1779. [Google Scholar] [CrossRef]
- Pipe, S.W.; Morris, J.A.; Shah, J.; Kaufman, R.J. Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J. Biol. Chem. 1998, 273, 8537–8544. [Google Scholar] [CrossRef]
- Shahani, T.; Covens, K.; Lavend’homme, R.; Jazouli, N.; Sokal, É.; Peerlinck, K.; Jacquemin, M. Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII. J. Thromb. Haemost. 2014, 12, 36–42. [Google Scholar] [CrossRef]
- Vehar, G.A.; Keyt, B.; Eaton, D.; Rodriguez, H.; O’Brien, D.P.; Rotblat, F.; Oppermann, H.; Keck, R.; Wood, W.I.; Harkins, R.N.; et al. Structure of human factor VIII. Nature 1984, 312, 337–342. [Google Scholar] [CrossRef] [PubMed]
- Lollar, P.; Hill-Eubanks, D.C.; Parker, C.G. Association of the factor VIII light chain with von Willebrand factor. J. Biol. Chem. 1988, 263, 10451–10455. [Google Scholar] [CrossRef]
- Kaufman, R.J.; Wasley, L.C.; Dorner, A.J. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J. Biol. Chem. 1988, 263, 6352–6362. [Google Scholar] [PubMed]
- Eaton, D.; Rodriguez, H.; Vehar, G.A. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986, 25, 505–512. [Google Scholar] [CrossRef]
- Gitschier, J.; Wood, W.I.; Goralka, T.M.; Wion, K.L.; Chen, E.Y.; Eaton, D.H.; Vehar, G.A.; Capon, D.J.; Lawn, R.M. Characterization of the human factor VIII gene. Nature 1984, 312, 326–330. [Google Scholar] [CrossRef] [PubMed]
- Antonarakis, S.E.; Rossiter, J.P.; Young, M.; Horst, J.; de Moerloose, P.; Sommer, S.S.; Ketterling, R.P.; Kazazian, H.H., Jr.; Negrier, C.; Vinciguerra, C.; et al. Factor VIII gene inversions in severe hemophilia A: Results of an international consortium study. Blood 1995, 86, 2206–2212. [Google Scholar] [CrossRef]
- Oldenburg, J.; Ananyeva, N.M.; Saenko, E.L. Molecular basis of haemophilia A. Haemophilia 2004, 10 (Suppl. S4), 133–139. [Google Scholar] [CrossRef]
- El-Maarri, O.; Olek, A.; Balaban, B.; Montag, M.; van der Ven, H.; Urman, B.; Olek, K.; Caglayan, S.H.; Walter, J.; Oldenburg, J. Methylation levels at selected CpG Sites in the factor VIII and FGFR3 genes, in mature female and male germ cells: Implications for male-driven evolution. Am. J. Hum. Genet. 1998, 63, 1001–1008. [Google Scholar] [CrossRef] [PubMed]
- Millar, D.S.; Krawczak, M.; Cooper, D.N. Variation of site-specific methylation patterns in the factor VIII (F8C) gene in human sperm DNA. Hum. Genet. 1998, 103, 228–233. [Google Scholar] [CrossRef] [PubMed]
- Kemball-Cook, G.; Tuddenham, E.G.; Wacey, A.I. The factor VIII structure and mutation resource site: HAMSTeRS Version 4. Nucleic Acids Res. 1998, 26, 216–219. [Google Scholar] [CrossRef]
- EAHAD Factor VIII Variant Database. Available online: https://f8-db.eahad.org/ (accessed on 12 June 2024).
- Carcao, M.; Goudemand, J. Inhibitors in Hemophilia: A Primer, 5th ed.; World Federation of Hemophilia: Montreal, QC, Canada, 2018. [Google Scholar]
- Kreuz, W.; Becker, S.; Lenz, E.; Martinez-Saguer, I.; Escuriola-Ettingshausen, C.; Funk, M.; Ehrenforth, S.; Auerswald, G.; Kornhuber, B. Factor VIII inhibitors in patients with hemophilia A: Epidemiology of inhibitor development and induction of immune tolerance for factor VIII. Semin. Thromb. Hemost 1995, 21, 382–389. [Google Scholar] [CrossRef]
- Oldenburg, J.; Schröder, J.; Brackmann, H.H.; Müller-Reible, C.; Schwaab, R.; Tuddenham, E. Environmental and genetic factors influencing inhibitor development. Semin. Hematol. 2004, 41, 82–88. [Google Scholar] [CrossRef]
- World Federation of Hemophilia. World Federation of Hemophilia Report on the Annual Global Survey 2022; World Federation of Hemophilia: Montreal, QC, Canada, 2023. [Google Scholar]
- Brinza, M.; Grigore, A.; Dragomir, M.; Jardan, D.; Jardan, C.; Balanescu, P.; Tarniceriu, C.C.; Badulescu, O.V.; Blag, C.; Tomuleasa, C.; et al. Large intron inversions in Romanian patients with hemophilia A—First Report. Medicina 2023, 59, 1821. [Google Scholar] [CrossRef] [PubMed]
- Oldenburg, J.; El-Maarri, O. New Insight into the Molecular Basis of Hemophilia A. Int. J. Hematol. 2006, 83, 96–102. [Google Scholar] [CrossRef]
- Bach, J.E.; Oldenburg, J.; Müller, C.R.; Rost, S. Mutational Spectrum and Deep Intronic Variants in the Factor VIII Gene of Haemophilia a Patients. Identification by next Generation Sequencing. Hamostaseologie 2016, 36, S25–S28. [Google Scholar]
- Gouw, S.C.; van den Berg, H.M.; Oldenburg, J.; Astermark, J.; de Groot, P.G.; Margaglione, M.; Thompson, A.R.; van Heerde, W.; Boekhorst, J.; Miller, C.H.; et al. F8 Gene Mutation Type and Inhibitor Development in Patients with Severe Hemophilia A: Systematic Review and Meta-Analysis. Blood 2012, 119, 2922–2934. [Google Scholar] [CrossRef]
- Johnsen, J.M.; Fletcher, S.N.; Huston, H.; Roberge, S.; Martin, B.K.; Kircher, M.; Josephson, N.C.; Shendure, J.; Ruuska, S.; Koerper, M.A.; et al. Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative. Blood Adv. 2017, 1, 824–834. [Google Scholar] [CrossRef]
- Oldenburg, J.; Pavlova, A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006, 12, 15–22. [Google Scholar] [CrossRef] [PubMed]
- Graw, J.; Brackmann, H.H.; Oldenburg, J.; Schneppenheim, R.; Spannagl, M.; Schwaab, R. Haemophilia A: From mutation analysis to new therapies. Nat. Rev. Genet. 2005, 6, 488–501. [Google Scholar] [CrossRef] [PubMed]
- Thompson, A.R. Structure and function of the factor VIII gene and protein. Semin. Thromb. Hemost. 2003, 29, 11–22. [Google Scholar] [CrossRef] [PubMed]
- Ogata, K.; Selvaraj, S.R.; Miao, H.Z.; Pipe, S.W. Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: Implications for genotyping. J. Thromb. Haemost. 2011, 9, 1183–1190. [Google Scholar] [CrossRef] [PubMed]
- Pattinson, J.K.; Millar, D.S.; McVey, J.H.; Grundy, C.B.; Wieland, K.; Mibashan, R.S.; Martinowitz, U.; Tan-Un, K.; Vidaud, M.; Goossens, M.; et al. The molecular genetic analysis of hemophilia A: A directed search strategy for the detection of point mutations in the human factor VIII gene. Blood 1990, 76, 2242–2248. [Google Scholar] [CrossRef] [PubMed]
- Castaman, G.; Giacomelli, S.H.; Mancuso, M.E.; D’Andrea, G.; Santacroce, R.; Sanna, S.; Santagostino, E.; Mannucci, P.M.; Goodeve, A.; Rodeghiero, F. Deep intronic variations may cause mild hemophilia A. J. Thromb. Haemost. 2011, 9, 1541–1548. [Google Scholar] [CrossRef] [PubMed]
- Atik, T.; Işık, E.; Onay, H.; Akgün, B.; Shamsali, M.; Kavakli, K.; Evim, M.; Tüysüz, G.; Özbek, N.Y.; Şahin, F.; et al. Factor 8 gene mutation spectrum of 270 patients with hemophilia A: Identification of 36 novel mutations. Turk. J. Hematol. 2020, 37, 145–153. [Google Scholar] [CrossRef]
- Reitter, S.; Sturn, R.; Horvath, B.; Freitag, R.; Male, C.; Muntean, W.; Streif, W.; Pabinger, I.; Mannhalter, C.; Austrian Molecular Haemophilia Study Group. Spectrum of causative mutations in patients with haemophilia A in Austria. Thromb. Haemost. 2010, 104, 78–85. [Google Scholar] [CrossRef] [PubMed]
- Santacroce, R.; Acquila, M.; Belvini, D.; Castaldo, G.; Garagiola, I.; Giacomelli, S.H.; Lombardi, A.M.; Minuti, B.; Riccardi, F.; Salviato, R.; et al. AICE-Genetics Study Group. Identification of 217 unreported mutations in the F8 gene in a group of 1,410 unselected Italian patients with hemophilia A. J. Hum. Genet. 2008, 53, 275–284. [Google Scholar] [CrossRef]
- Klopp, N.; Oldenburg, J.; Uen, C.; Schneppenheim, R.; Graw, J. 11 hemophilia A patients without mutations in the factor VIII encoding gene. Thromb. Haemost. 2002, 88, 357–360. [Google Scholar] [CrossRef]
- Mazurier, C.; Dieval, J.; Jorieux, S.; Delobel, J.; Goudemand, M. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood 1990, 75, 20–26. [Google Scholar] [CrossRef]
- Gaucher, C.; Jorieux, S.; Mercier, B.; Oufkir, D.; Mazurier, C. The “Normandy” variant of von Willebrand disease: Characterization of a point mutation in the von Willebrand factor gene. Blood 1991, 77, 1937–1941. [Google Scholar] [CrossRef]
- Nichols, W.C.; Seligsohn, U.; Zivelin, A.; Terry, V.H.; Hertel, C.E.; Wheatley, M.A.; Moussalli, M.J.; Hauri, H.P.; Ciavarella, N.; Kaufman, R.J.; et al. Mutations in the ER–Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell 1998, 93, 61–70. [Google Scholar] [CrossRef] [PubMed]
- Nichols, W.C.; Terry, V.H.; Wheatley, M.A.; Yang, A.; Zivelin, A.; Ciavarella, N.; Stefanile, C.; Matsushita, T.; Saito, H.; de Bosch, N.B.; et al. ERGIC-53 gene structure and mutation analysis in 19 combined factors V and VIII deficiency families. Blood 1999, 93, 2261–2266. [Google Scholar] [PubMed]
- Zhang, B.; Cunningham, M.A.; Nichols, W.C.; Bernat, J.A.; Seligsohn, U.; Pipe, S.W.; McVey, J.H.; Schulte-Overberg, U.; de Bosch, N.B.; Ruiz-Saez, A.; et al. Bleeding due to disruption of a cargo-specific ER-To-Golgi transport complex. Nat. Genet. 2003, 34, 220–225. [Google Scholar] [CrossRef] [PubMed]
- Schwaab, R.; Brackmann, H.H.; Meyer, C.; Seehafer, J.; Kirchgesser, M.; Haack, A.; Olek, K.; Tuddenham, E.G.; Oldenburg, J. Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb. Haemost. 1995, 74, 1402–1406. [Google Scholar] [CrossRef]
- Goodeve, A.C.; Williams, I.; Bray, G.L.; Peake, I.R. Relationship between Factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (RecombinateTM). Recombinate PUP Study Group. Thromb. Haemost. 2000, 83, 844–848. [Google Scholar] [CrossRef]
- Hay, C.R. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998, 4, 558–563. [Google Scholar] [CrossRef]
- Garagiola, I.; Palla, R.; Peyvandi, F. Risk factors for inhibitor development in severe hemophilia A. Thromb. Res. 2018, 168, 20–27. [Google Scholar] [CrossRef]
- Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015, 17, 405–424. [Google Scholar] [CrossRef]
Figure 1.
Distribution of variants by exon location.
Figure 2.
Mutational profile in (%) 187 patients with HA from Romania.
Figure 3.
Mutational profile in (%) 156 patients with severe HA from Romania.
Figure 4.
Mutational profile in (%) 31 patients with mild/moderate HA from Romania.
Table 1.
Description of variants in F8 gene identified in this study.
| Exon/Intron | Protein Domain | Nucleotide Change | Codon Change | Amino Acid Change | Variant Type | Novel/Known | No of Patients | Phenotype | Inhibitor | Criteria | Classification |
|---|---|---|---|---|---|---|---|---|---|---|---|
| E1 | A1 | c.71A>G | TAC>TGC | p.(Tyr24Cys) | missense | known | 1 | moderate | no | PM1 PM2 PP2 PP4 | LP |
| E1 | A1 | c.97T>C | TGG>CGG | p.(Trp33Arg) | missense | novel | 1 | severe | no | PM1 PM2 PP2 PP4 | LP |
| E2 | A1 | c.202A>G | ACT>GCT | p.(Thr68Ala) | missense | known | 1 | severe | no | PM1 PM2 PP2 PP4 | LP |
| E3 | A1 | c.292G>A | GAG>AAG | p.(Glu98Lys) | missense | known | 1 | severe | no | PM1 PM2 PP2 PP4 | LP |
| E3 | A1 | c.326A>G | AAC>AGC | p.(Asn109Ser) | missense | novel | 2 | severe | no | PM1 PM2 PP1 PP2 | LP |
| E4 | A1 | c.541G>A | GTG>ATG | p.(Val181Met) | missense | known | 3 | mild x3 | no | PS3 PS4 PM1 PP2 | P |
| E5 | A1 | c.641T>G | TTT>TGT | p.(Phe214Cys) | missense | novel | 4 | mild x1/moderate x2/severe x1 | no | PM1 PM2 PM5 PP2 | LP |
| E7 | A1 | c. 871G>A | GAA>AAA | p.(Glu291Lys) | missense | known | 1 | moderate | no | PS3 PS4 PM1 PP2 | P |
| E7 | A1 | c.985T>G | TGT>GGT | p.(Cys329Gly) | missense | novel | 1 | severe | no | PM1 PM2 PM5 PP2 | LP |
| E8 | A1 | c.1016T>C | ATG>ACG | p.(Met339Thr) | missense | known | 1 | severe | no | PM1 PM2 PP1 PP2 | LP |
| E8 | a1 | c.1171C>T | CGC>TGC | p.(Arg391Cys) | missense | known | 1 | moderate | no | PS3 PS4 PM1 PP2 | P |
| E8 | a1 | c.1172G>A | CGC>CAC | p.(Arg391His) | missense | known | 7 | moderatex3/severex4 | no | PS3 PS4 PM1 PP2 | P |
| E8 | A2 | c.1203G>T | TGG>TGT | p.(Trp401Cys) | missense | novel | 2 | moderate x2 | no | PM1 PM2 PP1 PP2 | LP |
| E8 | A2 | c.1244C>T | GCT>GTT | p.(Ala415Val) | missense | known | 1 | severe | no | PM1 PM2 PP1 PP2 | LP |
| E9 | A2 | c.1315G>A | GGT>AGT | p.(Gly439Ser) | missense | known | 1 | severe | no | PM1 PM2 PM5 PP2 | LP |
| E10 | A2 | c.1492G>A | GGA>AGA | p.(Gly498Arg) | missense | known | 1 | moderate | no | PS3 PS4 PM1 PP2 | P |
| E11 | A2 | c.1595G>C | TGG>TCG | p.(Trp532Ser) | missense | novel | 1 | severe | no | PM1 PM2 PP2 PP4 | LP |
| E11 | A2 | c.1648C>T | CGC>TGC | p.(Arg550Cys) | missense | known | 1 | mild | no | PS3 PS4 PM1 PP2 | P |
| E11 | A2 | c.1683T>G | GAT>GAG | p.(Asp561Glu) | missense | novel | 1 | moderate | no | PM1 PM2 PM5 PP2 | LP |
| E13 | A2 | c.1909A>G | AAT>GAT | p.(Asn637Asp) | missense | known | 1 | severe | no | PM1 PM2 PM5 PP2 | LP |
| E13 | A2 | c.1990C>G | CAG>GAG | p.(Gln664Glu) | missense | novel | 1 | severe | no | PM1 PM2 PP1 PP2 | LP |
| E13 | A2 | c.2048A>G | TAT>TGT | p.(Tyr683Cys) | missense | known | 3 | severe x3 | no | PS3 PS4 PM1 PP2 | P |
| E14 | A2 | c.2148T>A | TTT>TTA | p.(Phe716Leu) | missense | novel | 1 | severe | no | PM1 PM2 PP1 PP2 | LP |
| E14 | A2 | c.2149C>T | CGG>TGG | p.(Arg717Trp) | missense | known | 1 | moderate | no | PS3 PS4 PM1 PP2 | P |
| E14 | A2 | c.2150G>A | CGG>CAG | p.(Arg717Gln) | missense | known | 1 | moderate | no | PS3 PS4 PM1 PP2 | P |
| E14 | A2 | c.2167G>A | GCC>ACC | p.(Ala723Thr) | missense | known | 1 | mild | no | PM1 PM2 PM5 PP2 | LP |
| E14 | A2 | c.2189G>C | TGT>TCT | p.(Cys730Ser) | missense | novel | 1 | severe | no | PM1 PM2 PP1 PP2 | LP |
| E14 | a3 | c.5122C>T | CGC>TGC | p.(Arg1708Cys) | missense | known | 2 | mild/moderate | no | PS3 PS4 PM1 PP2 | P |
| E16 | A3 | c.5398C>T | CGT>TGT | p.(Arg1800Cys) | missense | known | 1 | severe | no | PS3 PS4 PM1 PP2 | P |
| E17 | A3 | c.5593G>T | GAT>TAT | p.(Asp1865Tyr) | missense | known | 1 | severe | no | PS3 PS4 PM1 PP2 | P |
| E17 | A3 | c.5815G>A | GCA>ACA | p.(Ala1939Thr) | missense | known | 1 | severe | no | PM1 PM2 PM5 PP2 | LP |
| E18 | A3 | c.5824G>A | GGC>AGC | p.(Gly1942Ser) | missense | known | 1 | severe | no | PM1 PM2 PP2 PP4 | LP |
| E19 | A3 | c.6046C>T | CGG>TGG | p.(Arg2016Trp) | missense | known | 4 | moderate x3/severe x1 | yes (1 patient) | PS3 PS4 PM1 PP2 | P |
| E23 | C1 | c.6506G>A | CGT>CAT | p.(Arg2169His) | missense | known | 1 | mild | no | PS3 PS4 PM1 PP2 | P |
| E23 | C1 | c.6533G>A | CGC>CAC | p.(Arg2178His) | missense | known | 1 | moderate | no | PS1 PS3 PS4 PM1 PP2 | P |
| E23 | C1 | c.6544C>T | CGC>TGC | p.(Arg2182Cys) | missense | known | 1 | severe | no | PS3 PS4 PM1 PP2 | P |
| E23 | C1 | c.6545G>A | CGC>CAC | p.(Arg2182His) | missense | known | 2 | severe x2 | no | PS3 PS4 PM1 PP2 | P |
| E24 | C2 | c.6683G>A | GGA>CAA | p.(Arg2228Gln) | missense | known | 1 | severe | yes | PS1 PS3 PS4 PM1 PP2 | P |
| E1 | signal peptide | c.4C>T | CAA>TAA | p.(Gln2*) | nonsense | novel | 1 | severe | no | PVS1 PM1 PM2 PM4 PP1 | P |
| E8 | a1 | c.1063C>T | CGA>TGA | p.(Arg355*) | nonsense | known | 1 | severe | no | PVS1 PM1 PM2 PM4 | P |
| E8 | A2 | c.1203G>A | TGG>TGA | p.(Trp401*) | nonsense | known | 1 | severe | no | PVS1 PM1 PM2 PM4 PP1 | P |
| E11 | A2 | c.1750C>T | CAG>TAG | p.(Gln584*) | nonsense | novel | 1 | severe | no | PVS1 PM1 PM2 PM4 | P |
| E12 | A2 | c.1804C>T | CGA>TGA | p.(Arg602*) | nonsense | known | 1 | severe | no | PVS1 PM1 PM2 PM4 | P |
| E14 | B | c.2440C>T | CGA>TGA | p.(Arg814*) | nonsense | known | 2 | severe x2 | no | PVS1 PM1 PM2 PM4 | P |
| E14 | B | c.3380G>A | TGG>TAG | p.(Trp1127*) | nonsense | novel | 2 | severe x2 | no | PVS1 PM1 PM2 PM4 PP1 | P |
| E14 | B | c.4128C>A | TAC>TAA | p.(Tyr1376*) | nonsense | known | 1 | severe | no | PVS1 PM1 PM2 PM4 PP1 | P |
| E14 | B | c.4408G>T | GAG>TAG | p.(Glu1470*) | nonsense | known | 1 | severe | yes | PVS1 PM1 PM2 PM4 | P |
| E17 | A3 | c.5766C>A | TGC>TGA | p.(Cys1922*) | nonsense | known | 1 | severe | no | PVS1 PM1 PM2 PM4 | P |
| E18 | A3 | c.5878C>T | CGA>TGA | p.(Arg1960*) | nonsense | known | 1 | severe | yes | PVS1 PM1 PM2 PM4 PP1 | P |
| E22 | C1 | c.6403C>T | CGA>TGA | p.(Arg2135*) | nonsense | known | 2 | severe x2 | no | PVS1 PM1 PM2 PM4 PP1 | P |
| E23 | C1 | c.6496C>T | CGA>TGA | p.(Arg2166*) | nonsense | known | 1 | severe | no | PVS1 PM1 PM2 PM4 | P |
| E25 | C2 | c.6743G>A | TGG>TAG | p.(Trp2248*) | nonsense | known | 1 | severe | yes | PVS1 PM1 PM2 PM4 PP1 | P |
| E2 | A1 | c.206_209delTGTT | p.(Leu69Leufs*2) | frameshift | novel | 1 | severe | no | PVS1 PM1 PM2 PM4 PP1 | P | |
| E14 | a2 | c.2218delG | p.(Asp740Thrfs*11) | frameshift | novel | 1 | severe | no | PVS1 PM1 PM2 PM4 | P | |
| E14 | B | c.3637delA | p.(Ile1213Phefs*5) | frameshift | known | 3 | severe x3 | no | PVS1 PM1 PM2 PM4 PP1 | P | |
| E14 | B | c.4085delA | p.(Asn1362Thrfs*1) | frameshift | novel | 1 | severe | no | PVS1 PM1 PM2 PM4 | P | |
| E14 | B | c.4370delC | p.(Ala1457Alafs*8) | frameshift | novel | 1 | moderate | no | PVS1 PM1 PM2 PM4 | P | |
| E14 | B | c.4372delA | p.(Lys1458Lysfs*7) | frameshift | known | 2 | severe x2 | no | PVS1 PM1 PM2 PM4 | P | |
| E14 | B | c.4377_4380delAAAT | p.(Lys1459Lysfs*4) | frameshift | novel | 1 | severe | no | PVS1 PM1 PM2 PM4 | P | |
| E19 | A3 | c.6082delG | p.(Met2029*) | frameshift | known | 1 | severe | yes | PVS1 PM1 PM2 PM4 | P | |
| E25 | C2 | c.6876_6877delCT | p.(Phe2294Serfs*90) | frameshift | known | 1 | severe | no | PVS1 PM1 PM2 PM4 | P | |
| E14 | B | c.2945dupA | p.(Asn982Lysfs*9) | frameshift | known | 1 | severe | no | PVS1 PM1 PM2 PM4 PP1 | P | |
| E14 | B | c.3300dupA | p.(Glu1101Argfs*16) | frameshift | known | 1 | severe | no | PVS1 PM1 PM2 PM4 PP1 | P | |
| E14 | B | c.3637duplA | p.(Ile1213Asnfs*28) | frameshift | known | 1 | severe | no | PVS1 PM1 PM2 PM4 | P | |
| E14 | B | c.4379dupA | p.(Asn1460Lysfs*1) | frameshift | known | 1 | severe | no | PVS1 PM1 PM2 PM4 PP1 | P | |
| I6 | c.787+3A>G | splice | known | 3 | severe x3 | no | PPM1 PM2 PP1 PP4 PP5 | LP | |||
| I9 | c.1444-1G>A | splice | novel | 1 | severe | no | PM1 PM2 PP1 PP4 | LP | |||
| I11 | c.1753-2A>C | splice | known | 1 | severe | no | PM1 PM2 PP1 PP4 | LP | |||
| I11 | c.1753-12T>A | splice | novel | 2 | moderate x2 | no | PM1 PM2 PP1 PP4 | LP | |||
| I17 | c.5816-2A>G | splice | known | 1 | severe | no | PPM1 PM2 PP1 PP4 PP5 | LP | |||
| Del. Ex. 1-6 | deletion | known | 1 | severe | yes | ||||||
| Del. Ex. 1-10 | deletion | novel | 1 | severe | no | ||||||
| Del ex.5-6 | deletion | known | 1 | severe | no | ||||||
| Dupl. ex. 2-14 | duplication | novel | 1 | severe | no | ||||||
| Dupl. ex. 16-22 | duplication | novel | 1 | severe | yes |
Abbreviations: E, exon; I, intron; LP, likely pathogenic; P, pathogenic.
Table 2.
Distribution of inhibitors according to the type of mutation.
| Mutation Type | Inversion 22 | Inversion 1 | Missense | Nonsense | Small Deletions | Small Duplications | Splice-Site Variants | Large Deletions | Large Duplications | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of patients | 65 | 5 | 57 | 17 | 12 | 4 | 8 | 3 | 2 | 14 | 187 |
| Patients with inhibitors | 7 | 2 | 2 | 3 | 1 | 0 | 0 | 1 | 1 | 0 | 17 |
| Inhibitor frequency | 10.77% | 40% | 3.51% | 17.65% | 8.33% | 0% | 0% | 33.33% | 50% | 0% | 9.09% |
Table 3.
Comparison of mutation frequencies in Romanian HA patients and other populations.
| HA-All Severities | Severe HA | Mild/Moderate HA | ||||||
|---|---|---|---|---|---|---|---|---|
| Mutation Type | Intron 22 Inversion | Intron 1 Inversion | Missense Variants | Nonsense Variants | Small Deletions and Insertions | Large Deletions | Large Duplications | Splice-Site Mutations |
| Romanian patients (n = 187) | 34.8% | 2.7% | 30.5% | 9.1% | 8.5% | 1.6% | 1.1% | 4.3% |
| Oldenburg et al. [21] (n = 846) | 35.7% | 1% | 38.2% | 9.3% | 10.1% | 3% | 0% | 2.6% |
| Bach et al. [22] (n = 2671) | 25.38% | 1.12% | 43.77% | 7.08% | 10.71% | 2.81% | 0.64% | 3.59% |
| Romanian patients (n = 156) | 41.7% | 3.2% | 19.2% | 10.9% | 9.7% | 1.9% | 1.3% | 3.8% |
| Gouw et al. [23] (n = 5383) | 45% | 2% | 15% | 10% | 16% | 3% | 0% | 3% |
| Johnsen et al. [24] (n = 1272) | 42% | 1.4% | 17.4% | 10.7% | 17.4% | NA | NA | 3.3% |
| Romanian patients (n = 31) | 0% | 0% | 87.1% | 0% | 3.2% | 0% | 0% | 6.5% |
| Johnsen et al. [24] (n = 1048) | 3.7% | 0.2% | 79.5% | 1.1% | 2% | NA | NA | 2.7% |
NA—not available.
Table 4.
Type of F8 gene mutation and inhibitor development in Romanian patient with HA versus other populations.
Table 4.
Type of F8 gene mutation and inhibitor development in Romanian patient with HA versus other populations.
| Mutation Type | Inhibitor Frequency in Romanian Patients (n = 187) | Inhibitor Frequency-Gouw et al. [22] Meta-Analysis (n = 922) | Inhibitor Frequency-Oldenburg et al. [24] (Bonn Centre Study + HAMSTERS Databese) |
|---|---|---|---|
| Intron 22 inversion | 10.77% | NA | 21% |
| Intron 1 inversion | 40% | NA | 17% |
| Nonsense mutations in the light chain | 33.33% | 43% | 40% |
| Nonsense mutations outside the light chain | 9.09% | 12% | 17% |
| Missense mutations in the light chain | 14.3% | 11% | 10% |
| Missense mutations outside the light chain | 0% | 6% | 3% |
| Small deletions and insertions in poly-A runs | 0% | 6% | 3% |
| Small deletions and insertions outside poly-A runs | 16.67% | 19% | 21% |
| Large deletions > 1 exon | 33.33% | 67% | 88% |
| Splice-site mutations | 0% | 7% | 17% |
NA—not available.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Grigore, A.; Dragomir, M.; Călugăru, O.-T.; Jardan, D.; Jardan, C.; Brînză, M.; Bălănescu, P.; Coriu, D. Mutational Profile in Romanian Patients with Hemophilia A. Int. J. Mol. Sci. 2024, 25, 8366. https://doi.org/10.3390/ijms25158366
AMA Style
Grigore A, Dragomir M, Călugăru O-T, Jardan D, Jardan C, Brînză M, Bălănescu P, Coriu D. Mutational Profile in Romanian Patients with Hemophilia A. International Journal of Molecular Sciences. 2024; 25(15):8366. https://doi.org/10.3390/ijms25158366
Chicago/Turabian StyleGrigore, Andra, Mihaela Dragomir, Onda-Tabita Călugăru, Dumitru Jardan, Cerasela Jardan, Melen Brînză, Paul Bălănescu, and Daniel Coriu. 2024. "Mutational Profile in Romanian Patients with Hemophilia A" International Journal of Molecular Sciences 25, no. 15: 8366. https://doi.org/10.3390/ijms25158366
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
